Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ReSTORE: Rezafungin vs Caspofungin in Candidemia and Invasive Candidiasis
NCT03667690Phase 3Completed
- Sponsor
- Cidara Therapeutics
- Start
- Oct 2018
- Primary completion
- Oct 2021
- Modality
- Cyclic Peptides, Antimicrobial Peptides, Small Molecules
- Countries
- 18
01
Overview
A Phase 3 trial of rezafungin in candidemia, invasive candidiasis, sponsored by Cidara Therapeutics. Started Oct 2018; status: completed.
02
Drugs
rezafungin
03
Conditions
candidemiainvasive candidiasis
Beyond the preview
Go deeper on NCT03667690.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03667690.